Basen was launched in 1994 in Japan as an improving agent for postprandial hyperglycemia in diabetes mellitus, with its mechanism of action of delaying the digestion and absorption of carbohydrate, resulting in improvement of postprandial hyperglycemia.
Masaomi Miyamoto, general manager of pharmaceutical development division of Takeda, said: “Once this application is approved, we will be able to offer a new treatment option of medicinal therapy for patients with IGT and healthcare providers who treat them.”